Objectives: The 2012 Surviving Sepsis Campaign pediatric guidelines recommend stress dose hydrocortisone in children experiencing catecholamine-dependent septic shock with suspected or proven absolute adrenal insufficiency. We evaluated whether stress dose hydrocortisone therapy in children with catecholamine dependent septic shock correlated with random serum total cortisol levels and was associated with improved outcomes. Design: Retrospective cohort study. Setting: Non-cardiac PICU. Patients: Critically ill children (1 mo to 18 yr) admitted between January 1, 2013, and December 31, 2013, with catecholamine dependent septic shock who had random serum total cortisol levels measured prior to potential stress dose hydrocortisone therapy. Interventions: None. Measurements and Main Results: The cohort was dichotomized to random serum total cortisol less than 18 mcg/dL and greater than or equal to 18 mcg/dL. Associations of stress dose hydrocortisone with outcomes: PICU mortality, PICU and hospital length of stay, ventilator-free days, and vasopressor-free days were examined. Seventy children with catecholamine-dependent septic shock and measured random serum total cortisol levels were eligible (16% PICU mortality). Although 43% (30/70) had random serum total cortisol less than 18 μg/dL, 60% (42/70) received stress dose hydrocortisone. Children with random serum total cortisol less than 18 μg/dL had lower severity of illness and lower Vasopressor Inotrope Scores than those with random serum total cortisol greater than or equal to 18 μg/dL (all p < 0.05). Children with stress dose hydrocortisone had higher severity of illness and PICU mortality than those without stress dose hydrocortisone (all p < 0.05). Mean random serum total cortisol levels were similar in children with and without stress dose hydrocortisone (21.1 vs 18.7 μg/dL; p = 0.69). In children with random serum total cortisol less than 18 μg/dL, stress dose hydrocortisone was associated with greater PICU and hospital length of stay and fewer ventilator-free days (all p < 0.05). In children with random serum total cortisol greater than 18 μg/dL, stress dose hydrocortisone was associated with greater PICU mortality and fewer ventilatorfree days and vasopressor-free days (all p < 0.05). Conclusions: Stress dose hydrocortisone therapy in children with catecholamine-dependent septic shock correlated more with severity of illness than random serum total cortisol levels and was associated with worse outcomes, irrespective of random serum total cortisol levels. (Pediatr Crit Care Med 2017; 18:e406-e414) Key Words: cortisol; critical illness; hydrocortisone; pediatrics; septic shock S evere sepsis and septic shock are leading causes of morbidity and mortality in children (1) (2) (3) (4) . The role of stress dose hydrocortisone (SDH) therapy in this setting to reverse shock associated with suspected or proven adrenal insufficiency continues to be a subject of considerable investigation. Guidelines from the Surviving Sepsis Campaign in 2012 recommend timely SDH therapy in children experiencing fluid refractory catecholamine-dependent septic shock with suspected or proven absolute adrenal insufficiency (grade 1A-strong recommendation based on high quality evidence) (5) . Although the pediatric subgroup guidelines do not explicitly define a threshold random serum total cortisol (rSTC) level to prescribe SDH therapy, indications for pediatric therapy are typically extrapolated from the adult guidelines state that "an inappropriately low rSTC level less than 18 μg/dL in a patient with shock would be considered an indication for steroid therapy along traditional adrenal insufficiency guidelines" (5, 6) .
Although the pathophysiologic changes in severe sepsis with fluid refractory catecholamine-dependent septic shock with suspected or proven absolute adrenal insufficiency provide biological plausibility for benefit from therapy with SDH (7) (8) (9) , clinical studies of SDH therapy to improve outcomes in both adults and children being managed for septic shock with suspected or proven absolute adrenal insufficiency have demonstrated equivocal results (10) (11) (12) (13) (14) (15) . Additionally, clinician surveys of attitudes and practice regarding SDH therapy in the setting of catecholamine-dependent pediatric septic shock with suspected or proven absolute adrenal insufficiency demonstrate wide variations in criteria for diagnosis of adrenal insufficiency and indications for therapy with SDH (16) (17) (18) . It is unclear whether the guideline specified rSTC cut-off of 18 μg/dL is a pragmatic threshold for SDH therapy in catecholamine-dependent pediatric septic shock with suspected or proven absolute adrenal insufficiency, and if SDH therapy based on this rSTC level is associated with improved outcomes.
The primary objective of our study was to evaluate the association of guideline-based SDH therapy in critically ill children experiencing fluid refractory catecholamine-dependent septic shock with clinical outcomes. Our secondary objective was to examine the correlations between SDH therapy, rSTC levels, and severity of illness.
MATERIALS AND METHODS

Study Design and Patient Selection
We performed a retrospective chart review study of critically ill children 1 month to 18 years old consecutively admitted to the PICU at The Children's Hospital of Philadelphia between January 1, 2013, and December 31, 2013. The PICU is a noncardiac medical-surgical unit with a capacity of 55 beds and annual volume of approximately 3,600 admissions. Critically ill children with catecholamine-dependent septic shock and rSTC levels measured prior to potential SDH therapy were included in this study. We excluded children with corrected gestational age less than 44 weeks, history of cardiac surgery within the preceding 6 months, and SDH administration prior to obtaining rSTC level. This study was approved by the Institutional Review Board for the Protection of Human Subjects with waiver of informed consent/assent.
Data Collection
The PICU and pharmacy databases were used to identify subjects with fluid refractory catecholamine-dependent septic shock. We screened for subjects with severe sepsis with or without shock based on International Classification of Diseases, 9th Edition (ICD-9) codes (995.92 for severe sepsis and 785.52 for septic shock) from the PICU database (maintained by PICU-trained clinical data abstractors, who manually review patient records to ensure accurate data entry using ICD codes, specifically ICD-9 at the time of this study). Subsequently, we manually examined patient records to identify subjects with fluid refractory catecholaminedependent septic shock per the study definition detailed below. Data were collected on subject demographic characteristics, illness severity, duration of invasive mechanical ventilation support, duration and number of vasopressor infusions, dose and duration of SDH administered, duration of taper from SDH, and rSTC levels by querying the electronic medical record (EMR), and PICU and Pharmacy databases. Details regarding specialty consultation with Endocrinology to evaluate for adrenal insufficiency and hypothalamic pituitary adrenal (HPA) axis testing were collected from the EMR. Data on primary and secondary outcomes were collected from the PICU database.
Definitions and Outcomes
The cohort was dichotomized to subjects with rSTC level less than 18 μg/dL and subjects with rSTC level greater than or equal to 18 μg/dL. SDH therapy was defined as initial hydrocortisone dose greater than or equal to 50 mg/m 2 (or ≥ 1 mg/kg, when length measurements were unavailable) followed by subsequent hydrocortisone dose greater than or equal to 50 mg/m 2 /d (or ≥ 1 mg/kg/d, when length measurements were unavailable), administered via any route for one or more doses. Septic shock was defined as shock state due to suspected or proven sepsis requiring antimicrobial therapy. Fluid refractory catecholamine dependence was defined as the continuous need for catecholamine infusion for 6 or more hours following initial fluid resuscitation (≥ 60 mL/kg of crystalloid and/or colloid solutions) in septic shock. For the purpose of this study, catecholamines (vasopressors) were considered to include dopamine greater than 5 μg/kg/min, vasopressin (when used to support circulatory shock), and any dose of dobutamine, epinephrine, norepinephrine, phenylephrine, and milrinone. The Vasopressor Inotrope Score at the time of rSTC level measurement was calculated as follows: dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + epinephrine (μg/kg/min) × 100 + norepinephrine (μg/kg/min) × 100 + phenylephrine (μg/kg/min) × 100 + vasopressin (U/kg/min) × 10,000 + milrinone (μg/kg/min) × 10 (19). Severity of illness was expressed as Pediatric Risk of Mortality (PRISM) III score at 12 hours (20) .
The primary clinical outcome of interest was PICU mortality. Secondary clinical outcomes included PICU length of stay (LOS), hospital LOS, ventilator-free days (VFD) at 28 days, vasopressorfree days (VPFD) at 28 days, and hospital-acquired infections (HAIs). Liberation from invasive mechanical ventilation for more than 24 hours and liberation from vasopressor infusion for more than 24 hours defined duration of invasive mechanical ventilation and duration of vasopressor support, respectively. For the purpose of this study, noninvasive ventilation support did not count toward duration of invasive mechanical ventilation. VFD was determined by subtracting total ventilator days from 28 in survivors. VPFD was determined by subtracting total vasopressor days from 28 in survivors. All subjects with total ventilator days greater than or equal to 28 days and all PICU nonsurvivors were assigned VFD equals to 0. Similarly, all subjects with total vasopressor days greater than or equal to 28 days and all PICU nonsurvivors were assigned VPFD equals to 0. HAI included central catheter-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated infections, surgical site infections, and nosocomial viral infections based on National Healthcare Safety Network criteria used in our institution (21) .
Statistical Analysis
Summary data for subject characteristics and outcomes were expressed as mean values and sds for normally distributed continuous variables and as median values with interquartile ranges for continuous variables that were not normally distributed. Categorical variables were reported as counts and percentages. We used t test (or nonparametric equivalent, Wilcoxon rank-sum test) for analysis of differences between distributions of continuous variables and Fisher exact test for analysis of differences between distributions of categorical variables. We tested the association between SDH and PICU mortality, adjusted for severity of illness, using a two-variable logistic regression model and reported adjusted odds ratios (ORs) with 95% CIs. Correlations between logtransformed rSTC levels and severity of illness (PRISM III scores) were tested with Pearson correlation. We did not correct our analyses for multiple comparisons and reported two-sided p values that were considered significant if p value less than 0.05. 
RESULTS
A total of 3,583 patients were admitted to the PICU between January 1, 2013, and December 31, 2013, of whom 240 patients had a diagnosis of severe sepsis with or without shock. After excluding 170 patients (145 without catecholamine-dependent septic shock, i.e., fluid responsive; 18 with fluid refractory catecholamine-dependent septic shock who received SDH but did not have measured rSTC levels; three with prior cardiac surgery within preceding 6 mo; and four with fluid refractory catecholamine-dependent septic shock but had rSTC levels drawn after SDH administration), 70 subjects met inclusion criteria for study enrollment. The PICU mortality for the study cohort was 16% (11 deaths). Thirty subjects (43%) had measured rSTC less than 18 μg/dL, while 42 subjects (60%) received SDH for fluid refractory catecholamine-dependent septic shock. Of subjects who received SDH therapy, 90% (38/42) were dosed based on body surface area calculated from length measurement obtained prior to SDH therapy. Specialty consultation with Endocrinology was obtained in seven subjects (10%) to assess for adrenal insufficiency, and HPA axis testing was performed in three subjects (4%) following completion of SDH therapy.
Outcomes by rSTC Levels
In comparison to subjects with rSTC level less than 18 μg/dL (n = 30), subjects with rSTC level greater than or equal to 18 μg/dL (n = 40) were sicker with higher PRISM III scores at 12 hours and higher Vasopressor Inotrope Scores at the time of rSTC level measurement ( Table 1 ) (both p < 0.05). Although 57% of subjects with rSTC level less than 18 μg/dL received SDH, up to 63% of subjects with rSTC level greater than or equal to 18 μg/dL received SDH (p = 0.63). The initial dose of SDH of 100 mg/m 2 was similar between the two groups (88% of subjects with rSTC level < 18 μg/dL vs 84% of subjects with rSTC level > 18 μg/dL; p = 1). There were no differences in the primary outcome of PICU mortality or secondary outcomes of PICU LOS, hospital LOS, VFD, VPFD, and HAI between the two groups based on rSTC cut-off level of 18 μg/dL (Table 1) . Outcomes by SDH Therapy Subjects who received SDH therapy (n = 42) were sicker with higher PRISM III scores at 12 hours, higher Vasopressor Inotrope Scores at the time of rSTC level measurement, and required more support with mechanical ventilation at the time of SDH therapy in comparison to subjects who did not receive SDH therapy (n = 28) ( Table 2 ). There were no significant differences in rSTC levels between the two groups (p = 0.69). Subjects with SDH therapy had higher PICU mortality than those without SDH therapy (unadjusted OR, 8.4; 95% CI, 1.2-70.2; p = 0.049).
After adjusting for PRISM III scores at 12 hours, SDH therapy continued to be independently associated with PICU mortality (adjusted OR, 6.7; 95% CI, 2.6-42.1; p = 0.039). Subjects with SDH therapy also had worse secondary clinical outcomes in comparison to subjects without SDH therapy (Table 2 ). In the subgroup of subjects with rSTC level less than 18 μg/dL, there were no differences in PRISM III scores at 12 hours or Vasopressor Inotrope Scores at the time of rSTC level measurement between those who received SDH therapy and those who did not. In this subgroup, SDH therapy was associated with greater PICU LOS and hospital LOS and fewer VFD (all p < 0.05) ( Table 3 ). In the subgroup of subjects with rSTC level greater than or equal to 18 μg/dL, subjects who received SDH therapy were sicker with higher PRISM III scores at 12 hours and Hospital-acquired infection, n (%) 1 (6) 1 (8) Vasopressor Inotrope Scores at the time of rSTC level measurement compared with those who did not receive SDH therapy. In this subgroup, SDH therapy was associated with higher PICU mortality and fewer VFD and VPFD (all p < 0.05) ( Table 3) .
Relationships of rSTC Levels, Severity of Illness, and SDH Therapy
Log-transformed rSTC levels were modestly positively correlated with PRISM III scores at 12 hours ( Fig. 1) (r = 0.3932; r 2 = 0.16; p < 0.001). SDH therapy was not significantly different across quintiles of rSTC levels, with maximum exposure in the lowest and highest quintiles ( Fig. 2A) (p = 0.177). SDH therapy proportionately increased with PRISM III scores at 12 hours (Fig. 2B) (p = 0.046).
DISCUSSION
The 2012 Surviving Sepsis Campaign pediatric guidelines recommend timely SDH therapy in children experiencing fluid refractory catecholamine-dependent septic shock with suspected or proven absolute adrenal insufficiency and also recommend obtaining an rSTC measurement prior to empiric SDH therapy (5) . Although the pediatric guidelines do not provide a clearly defined rSTC threshold level or make any recommendation on adrenocorticotropic hormone (ACTH) stimulation testing, the adult guidelines explicitly recommend against using the ACTH stimulation test and state that "an inappropriately low random cortisol level (< 18 μg/dL) in a patient with shock would be considered an indication for steroid therapy along traditional adrenal insufficiency guidelines" (grade 2B-weak recommendation based on moderate quality evidence). Thus, the guidelines suggest that the rSTC level less than 18 μg/dL is a useful marker to identify the subset of patients who are sicker (presumably due to the added comorbidity of adrenal insufficiency), and therefore more likely to benefit from SDH therapy resulting in improved clinical outcomes. The results of our study, however, do not support this recommendation. The subgroup of children with rSTC less than 18 μg/dL in our study were less sick with lower PRISM III scores at 12 hours and lower Vasopressor Inotrope Scores at the time of rSTC level measurement, in comparison to the subgroup with rSTC level greater than or equal to 18 μg/dL (Table 1) . Further, SDH exposure in the subgroup with rSTC less than 18 μg/dL was associated with worse clinical outcomes in comparison with those not exposed to SDH within this subgroup (Table 3 ). The findings of our study raise the important question of whether the rSTC level is the appropriate marker to identify adrenal insufficiency and to prospectively guide SDH therapy in critically ill children experiencing fluid refractory catecholamine-dependent septic shock. Although low rSTC levels in children with severe meningococcemia may directly reflect acute adrenal insufficiency (Waterhouse-Friderichsen syndrome) (22) (23) (24) , it is unclear whether rSTC levels directly correlate with adrenal function in the case of other critical illness settings such as nonmeningococcal sepsis or trauma (25) . The findings of our study are similar to other studies of critically ill children with severe sepsis (either alone or in combination with other disease entities) that have observed strong positive correlation between rSTC levels and mortality, with higher levels in nonsurvivors (26) (27) (28) . Elevated rSTC levels in these circumstances likely arise due to ACTH independent mediators of release as well as from decreases in metabolism and clearance of cortisol as an adaptive mechanism in times of acute stress (29, 30) . Simultaneously, ACTH concentrations decrease largely via negative feedback from elevated cortisol levels. This phenomenon of low ACTH and high cortisol has been termed "ACTH cortisol dissociation" and reflects HPA axis dysfunction in critical illness (30) . Additionally, prolonged critical illness also appears to affect ACTH signaling with negative effects on adrenal structure and function that may result in decreased adrenal responsiveness to exogenous ACTH administration (31) . These complex alterations in HPA axis function during critical illness clearly call into question our current choice of the rSTC level as a simplified biomarker of adrenal function during severe sepsis and/or septic shock.
Interestingly, we observed that SDH therapy correlated to a greater extent with severity of illness than rSTC levels, especially when rSTC level greater than or equal to 18 μg/dL. This raises the important question of whether clinicians felt compelled to attempt SDH therapy in critically ill children with greater severity of illness and more vasopressor support as a "last ditch" effort, particularly in those with rSTC level greater than or equal to 18 μg/dL who may have been at higher risk of worse outcomes. This "epiphenomenon" is similar to the well-described associations of worse outcomes with use of medications such as sodium bicarbonate and calcium during prolonged resuscitative efforts in pediatric cardiac arrest (32, 33) .
Our study adds to the growing debate about the appropriate indication for SDH therapy during fluid refractory catecholamine-dependent pediatric septic shock based on current guidelines. As in other studies of critically ill children (13, 14, 28, 34, 35) , SDH therapy conferred no definite benefits and, on the contrary, appeared to be associated with harm in this study cohort. Corticosteroids have numerous side effects including hyperglycemia, myopathy, and delayed wound healing that predispose to morbidity and prolonged PICU dependency (36) . Recent studies on gene expression have observed that adaptive immune response may be repressed by corticosteroids in children with septic shock (37) . Additionally, higher risk subclasses in children with septic shock based on gene expression profiles appear to have worse outcomes with corticosteroid therapy (38) .
The limitations of our study include the small sample from a single center. It is possible that clinician practice is different in other centers and the results from our single center may not be generalizable. Due to the retrospective design of the study, the potential for bias arises. In the absence of explicit clinician documentation of indication for SDH therapy, we assumed that SDH was used for management of fluid refractory catecholamine-resistant shock in the relevant setting. It is also possible that a different threshold for rSTC level (e.g., 9 μg/dL) might have resulted in different results, but the small number of subjects with rSTC level less than 9 μg/dL precluded us from being able to effectively test the discriminant ability of this level. Additionally, the observed association of SDH therapy with worse outcomes does not imply a direct causality.
Although updated pediatric guidelines for therapy with SDH in children with septic shock are awaited, the recently published 2016 Surviving Sepsis Campaign adult guidelines recommend against SDH therapy if hemodynamic stability can be restored with adequate fluid resuscitation and vasopressor therapy (39) . The updated adult guidelines also do not make any reference to a specific rSTC level threshold to initiate SDH therapy in patients with septic shock. Currently, the Steroids in Fluid and Vasoactive Infusion Dependent Pediatric Shock is a pilot randomized controlled trial that is underway to assess feasibility of attempting a larger multicenter trial based on ability to recruit subjects, appropriateness of eligibility criteria, and adherence to the treatment protocol (40) . The larger trial is expected to help establish the role for SDH therapy in children with fluid and vasoactive infusion dependent shock.
CONCLUSIONS
SDH therapy in children with catecholamine-dependent septic shock correlates more with severity of illness than rSTC levels and is associated with worse outcomes, irrespective of rSTC levels. Based on our pragmatic observations, the rSTC cutoff of 18 μg/dL is a poorly discriminant marker for adrenal insufficiency in critically ill children with fluid refractory catecholamine-dependent septic shock. A prospective randomized controlled trial is necessary to determine if SDH is efficacious and safe in fluid refractory catecholamine-dependent septic shock in children.
